ARA-290
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
An erythropoietin-derived peptide engineered to spur nerve and tissue repair without raising red blood cell counts, marketed for neuropathic pain and diabetic metabolic support. Evidence rests on Phase 2 trials showing gains in nerve density, pain, and HbA1c, but no Phase 3 data exists and long-term safety is unknown. One trial had serious adverse events including an unrelated death, and non-trial supply is unregulated. Not FDA-approved; banned by WADA.
Read Full recordStudied uses & evidence
Studied uses(8)
Regenerates small nerve fibers, shown as increased corneal nerve fiber area in a Phase 2 trial
MediumSmall placebo-controlled trial found increased corneal nerve fiber area at 4 mg dose in sarcoidosis patients.
Reduces neuropathic pain — significant improvements in PainDetect and SFNSL scores in both sarcoidosis and diabetic neuropathy patients
MediumHuman trials show pain score gains, but the largest trial's effect missed significance.
Improves metabolic control — significant reductions in HbA1c (p=0.002), cholesterol/HDL ratio (p=0.039), and triglycerides (p=0.043) in diabetic patients
MediumSingle small trial found improved HbA1c, cholesterol ratio, and triglycerides in diabetics.
Evidence limits
- Evidence Level
- Early Clinical (Phase I/II)
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(8)
Risks = level of concern: High · Moderate · Low · Theoretical
Not approved by any regulatory agency — quality and purity of non-clinical-trial sources cannot be guaranteed
HighProhibited by WADA — use may result in anti-doping violations for competitive athletes
HighInvestigational compound — long-term safety profile not established; no Phase 3 data available
HighSerious adverse events in Phase 2 diabetes trial: 4 SAEs including 1 renal insufficiency event (possibly related) and 1 fatal myocardial infarction (judged unrelated by safety committee)
ModerateNo long-term carcinogenicity or reproductive toxicity data available
ModeratePotential immune modulation effects — caution advised when combining with immunosuppressants or biologic anti-inflammatory drugs
TheoreticalInjection site reactions (mild) reported in clinical trials
TheoreticalHeadache reported as a common mild adverse event
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.